Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 2—February 2014
Research

Human Antibody Responses to Avian Influenza A(H7N9) Virus, 2013

Li Guo1, Xi Zhang1, Lili Ren1, Xuelian Yu1, Lijuan Chen1, Hongli Zhou, Xin Gao, Zheng Teng, Jianguo Li, Jiayu Hu, Chao Wu, Xia Xiao, Yiyi Zhu, Quanyi Wang, Xinghuo Pang, Qi Jin2, Fan Wu2, and Jianwei Wang2Comments to Author 
Author affiliations: MOH Key Laboratory of Systems Biology of Pathogens, Beijing, People’s Republic of China (L. Guo, L. Ren, J. Li, Q. Jin, J. Wang); Institute of Pathogen Biology, Beijing (L. Guo, L. Ren, H. Zhou, X. Gao, J. Li, C. Wu, X. Xiao, Q. Jin, J. Wang); Shanghai Municipal Center for Disease Control and Prevention, Shanghai, People’s Republic of China (X. Zhang, X. Yu, Z. Teng, J. Hu, Y. Zhu, F. Wu); Beijing Municipal Center for Disease Control and Prevention, Beijing (L. Chen, Q. Wang, X. Pang)

Main Article

Figure 3

Association between antibody responses against H7 and seasonal subtypes in patients infected with influenza A(H7N9) virus, China. A) Levels of IgG against H1 and H3 in serum samples after symptom onset. IgG in samples taken at acute-phase (≤7 days), convalescent-phase (17–37days,) and 102–125 days after symptom onset were titrated by ELISA with recombinant H1 and H3 hemagglutinin antigens, respectively. IgG titers were transformed to log10. Bars indicate SE. B and C) Correlation between IgG agai

Figure 3. Association between antibody responses against H7 and seasonal subtypes in patients infected with influenza A(H7N9) virus, ChinaA) Levels of IgG against H1 and H3 in serum samples after symptom onsetIgG in samples taken at acute-phase (≤7 days), convalescent-phase (17–37days,) and 102–125 days after symptom onset were titrated by ELISA with recombinant H1 and H3 hemagglutinin antigens, respectivelyIgG titers were transformed to log10Bars indicate SEB and C) Correlation between IgG against H3 (B) and H1 (C) in acute-phase serum and against H7 in convalescent-phase serum**p<0.01.

Main Article

1These authors contributed equally to this article and are co–first authors.

2These authors contributed equally to this article and are co–senior authors.

Page created: January 17, 2014
Page updated: January 17, 2014
Page reviewed: January 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external